Pluri Inc.

Pluri Inc. is a biotechnology company that utilizes a proprietary 3D cell expansion platform. This platform is supported by an in-house, industrial-scale cell manufacturing facility that operates in accordance with Good Manufacturing Practice ("GMP") standards on a self-declared basis. The platform is designed for scalable, cost-efficient, and reproducible expansion of human, plant, and animal cells. It supports cell-based products, services, therapeutics, and related technologies across two primary application areas: Human Health and Longevity, and Foodtech and Bio-Farming. Pluri Inc. was incorporated in Nevada on May 11, 2001. The company has a wholly owned subsidiary, Pluri Biotech Ltd., incorporated in Israel. Pluri Biotech established Pluristem GmbH, a wholly owned subsidiary incorporated in Germany, in January 2020. In November 2021, Pluri Biotech established Ever After Foods, a subsidiary incorporated in Israel, in which Pluri Biotech holds approximately 69% of the issued and outstanding shares. In March 2024, Pluri Biotech established Coffeesai, a wholly owned subsidiary incorporated in Israel. On April 28, 2025, Pluri Inc. completed an acquisition of approximately 79% of the equity in Kokomodo, which is currently a majority-owned Israeli subsidiary of Pluri Biotech. In November 2025, Pluri Biotech established Cellav™, a wholly owned subsidiary incorporated in Israel. The company's operations focus on the research, development, manufacturing, and commercialization of cell-based products, therapeutics, and related technologies within its two primary application areas. The 3D cell expansion platform uses a synthetic scaffold to create a 3D environment for cell growth and an automated manufacturing process for consistent production of cell products at scale.